Breast Cancer Research Foundation

The medication was approved in combination with hormone therapy, with or without a CDK4/6 inhibitor. Key Takeaways The FDA has approved gedatolisib for certain people with HR-positive/HER2-negative breast cancer. Patients taking gedatolisib must also be on a specific hormone therapy and may also receive a CDK4/6 inhibitor. Progression-free survival with the combination of all three medications was more than 9 months, compared to 2 months for hormone therapy alone.

Key Takeaways Elizabeth Hurley reflects on 30 years of supporting breast cancer research. The star emceed the annual Hot Pink Party for the Breast Cancer Research Foundation. “Still one in eight women will be diagnosed with breast cancer, and we still have a long way to go,” she said.

At 45 years old, Jessica Conwell received a life-changing diagnosis that led her husband, Matt, to take action. Jessica Conwell met her husband, Matt, at a college retreat in 1996. The pair married two years later and attended graduate school together near Portland, Oregon. They built a life centered on friendship, shared adventures, and unwavering support for one another—something that would soon be put to the test.

Find thoughtful gifts for breast cancer survivors that support lifesaving research through the Breast Cancer Research Foundation With more than 4 million breast cancer survivors living in the U.S. today, most of us know someone who has been impacted by the disease. When caught early, five-year survival rates are incredibly high; and new breakthroughs are happening all the time—at a faster pace.

All about this breast cancer subtype, how it behaves, and why there is cause for optimism Key Takeaways Hormone receptor (HR)-positive breast cancer is the most common subtype and is driven by estrogen and progesterone hormones. Endocrine therapy blocks or lowers these hormones and is a highly effective targeted treatment. While HR-positive breast cancer often grows more slowly, it can return years after treatment, making long-term therapy and follow-up important.

BCRF-supported clinical trial signals long-term efficacy of reducing chemotherapy in some patients with HER2-positive breast cancer Key Takeaways Results from a phase 2 clinical trial study supported by the Breast Cancer Research Foundation showed that a shorter treatment regimen was effective for some women with HER2-positive breast cancer. The abbreviated treatment regimen reduces the duration and intensity of chemotherapy.

Results from the Breast Cancer Research Foundation investigator-led clinical trials underpin approvals Key takeaways These approvals give doctors more treatment options for patients with mTNBC. Because mTNBC is aggressive and fast-growing, choosing a powerful first-line treatment is critical. Trodelvy’s efficacy as a first-line treatment may improve outcomes, providing a profound impact on patients’ lives.

BCRF-funded research found that changes in AI-derived risk scores may reveal important clues about future breast cancer risk years before diagnosis Key Takeaways BCRF-funded researchers found that AI-generated breast cancer risk scores from routine mammograms change over time and may reveal important clues about future breast cancer risk. Risk scores increased years before diagnosis in women who later developed breast cancer, while remaining stable in women who stayed cancer-free.

And Early Career Awards support up-and-coming breast cancer researchers The 2026 American Society of Clinical Oncology (ASCO) key takeaways included updates in the world of metastasis, GLP-1 use and breast cancer, and more. The event also highlighted researchers making an impact in the field of oncology, including the Breast Cancer Research Foundation (BCRF) investigators, who received top honors at the annual meeting.

Here’s what experts want you to know about the treatment. Common breast cancer treatments include a wide range of strategies from chemotherapy to lumpectomies, but the Breast Cancer Research Foundation (BCRF) scientists are working towards more effective options. One of the possibilities is cryoablation for low-risk breast cancer. You may be familiar with the concept, as it’s a treatment used for conditions like skin cancer and irregular heart rhythms.